Literature DB >> 28577953

The impact of preoperative elevated serum C-reactive protein on postoperative morbidity and mortality after anatomic resection for lung cancer.

Alberto Lopez-Pastorini1, Richard Riedel2, Aris Koryllos3, Frank Beckers4, Corinna Ludwig5, Erich Stoelben6.   

Abstract

INTRODUCTION: The aim of this study was to determine whether preoperative elevated serum C-reactive protein (CRP) is an independent risk factor of postoperative morbidity and mortality after pulmonary resection for lung cancer.
MATERIAL AND METHODS: A retrospective analysis of prospectively collected data on 1414 consecutive patients that underwent an anatomic resection for lung cancer was performed. Patients' characteristics, operative procedures and the postoperative outcome were assessed with a standardised data entry form. Univariate and multivariate analyses were conducted to identify factors that affect morbidity and mortality.
RESULTS: Postoperative complications occurred in 35.5% of the patients. The mortality rate was 3.2%. Patients with preoperative C-reactive protein above 40mg/l showed more overall complications and a higher mortality than patients below this limit. Patients with a CRP level between 3mg/l and 40mg/l had no significant increase in morbidity and mortality compared to patients with values ​​below the detection limit (< 3mg/l).
CONCLUSIONS: Preoperative serum C-reactive protein level is an independent and significant indicator for elevated morbidity and mortality after pulmonary resection. We propose the evaluation of CRP levels as a preoperative diagnostic modality of risk assessment in addition to standardised functional testing.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  C-reactive protein; Lung cancer; Postoperative complications; Postoperative mortality

Mesh:

Substances:

Year:  2017        PMID: 28577953     DOI: 10.1016/j.lungcan.2017.05.003

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  6 in total

1.  M2 tumor-associated macrophages promote tumor progression in non-small-cell lung cancer.

Authors:  Ryota Sumitomo; Tatsuya Hirai; Masaaki Fujita; Hiroaki Murakami; Yosuke Otake; Cheng-Long Huang
Journal:  Exp Ther Med       Date:  2019-09-30       Impact factor: 2.447

2.  Correlation between STK33 and the pathology and prognosis of lung cancer.

Authors:  Yi Lu; Jie Tang; Wenmei Zhang; Ce Shen; Ling Xu; Danrong Yang
Journal:  Oncol Lett       Date:  2017-08-17       Impact factor: 2.967

3.  Multi-Omics Analysis of Cancer Cell Lines with High/Low Ferroptosis Scores and Development of a Ferroptosis-Related Model for Multiple Cancer Types.

Authors:  Guangyao Shan; Huan Zhang; Guoshu Bi; Yunyi Bian; Jiaqi Liang; Besskaya Valeria; Dejun Zeng; Guangyu Yao; Cheng Zhan; Hong Fan
Journal:  Front Cell Dev Biol       Date:  2021-12-06

4.  Clinical and bronchoscopic aspects of bronchial healing after sleeve resection for lung cancer: a multivariate analysis on 541 cases.

Authors:  Alberto Lopez-Pastorini; Christoph Eckermann; Aris Koryllos; Thomas Galetin; Corinna Ludwig; Michaela Hammer-Hellmig; Erich Stoelben
Journal:  J Thorac Dis       Date:  2022-04       Impact factor: 2.895

5.  Pretreatment advanced lung cancer inflammation index (ALI) for predicting early progression in nivolumab-treated patients with advanced non-small cell lung cancer.

Authors:  Takayuki Shiroyama; Hidekazu Suzuki; Motohiro Tamiya; Akihiro Tamiya; Ayako Tanaka; Norio Okamoto; Kenji Nakahama; Yoshihiko Taniguchi; Shun-Ichi Isa; Takako Inoue; Fumio Imamura; Shinji Atagi; Tomonori Hirashima
Journal:  Cancer Med       Date:  2017-11-18       Impact factor: 4.452

6.  Risk Factors for Duodenal Stump Leakage after Laparoscopic Gastrectomy for Gastric Cancer.

Authors:  Lihu Gu; Kang Zhang; Zefeng Shen; Xianfa Wang; Hepan Zhu; Junhai Pan; Xin Zhong; Parikshit Asutosh Khadaroo; Ping Chen
Journal:  J Gastric Cancer       Date:  2020-02-17       Impact factor: 3.720

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.